Inaticabtagene autoleucel clinical trials
How each study uses inaticabtagene autoleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the inaticabtagene autoleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Juventas Cell Therapy Ltd. (8) · Institute of Hematology & Blood Diseases Hospital, China (1)
Studies
Open first, then newest update. How each study uses inaticabtagene autoleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of TherapyNot yet recruitingPhase 1Juventas Cell Therapy Ltd.NCT07091370Written as Inaticabtagene Autoleucel Injection
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)RecruitingPhase 1/2Juventas Cell Therapy Ltd.NCT05667506Written as single dose of CNCT19
- Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic LeukemiaRecruitingPhase 2Juventas Cell Therapy Ltd.NCT04684147Written as single dose of CNCT19
- Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune ThrombocytopeniaRecruitingPhase 1Juventas Cell Therapy Ltd.NCT06826430Written as Inaticabtagene autoleucel Injection
- Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune DiseasesRecruitingEarly Phase 1Juventas Cell Therapy Ltd.NCT06316791Written as single dose of CNCT19
- Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingPhase 2Juventas Cell Therapy Ltd.NCT04586478Written as single dose of CNCT19
- Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.RecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06608732Written as Inaticabtagene autoleucel
- A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedPhase 1Juventas Cell Therapy Ltd.NCT04230473Written as single dose of CNCT19
- A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin LymphomaCompletedPhase 1Juventas Cell Therapy Ltd.NCT04232826Written as single dose of CNCT19
Codes
What other systems call inaticabtagene autoleucel · ClinicalTrials.gg INT018330
- UNII (FDA) W8VE86L4EUINATICABTAGENE AUTOLEUCELOne source FDA
- NCI Thesaurus C199061Inaticabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W8VE86L4EU | INATICABTAGENE AUTOLEUCEL | One source FDA |
| NCI Thesaurus | C199061 | Inaticabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.